At the news
? NEUTRALIMPACT 2/10 SC 13G/A filed Nov 13, 2026 at 13:51 ET
Capital World Investors filed an amended Schedule 13G disclosing a 10.4% passive stake in Alnylam Pharmaceuticals as of September 30, 2026, up from a prior filing. This is a routine update for a large passive holder and does not signal any change in investment intent or control.
- Capital World Investors reported beneficial ownership of 13,934,539 shares of Alnylam common stock, representing 10.4% of shares outstanding as of September 30, 2026.
- The filing is an amendment to Schedule 13G, certifying passive investment intent under Rule 13d-1(b).
- The stake increased from the prior filing (May 2026), which disclosed a lower percentage but no exact prior figure is stated in this document.
- The filing was made on November 13, 2026, with a signature date of November 11, 2026.
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access